Loading stock data…
ABVX
$99.00-3.72 (-3.62%)
Market OpenUpdated 3:02 PM EDT
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ABIVAX Société Anonyme in the Healthcare sector is trading at $99.00 with a market capitalization of $7.2B. Wall Street consensus targets $149.09 (11 analysts), implying a +50.6% move over the next 12 months. The stock is currently 33% below its 52-week high of $148.83, remaining 10.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +50.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$56.23M↑ | -$71.65M↑ | -$80.71M↓ | -$46.50M↑ | -$47.20M |
| Net Income | -$48.47M↑ | -$81.96M↑ | -$153.36M↓ | -$48.41M↑ | -$52.37M |
Peer Comparison
JNJUNHPFE
Fundamentals
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate inclu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-77.33%
Volume
Today's trading volume
1.07M
Recent News
High Growth Tech Stocks To Watch In The Global Market
Global markets have been buoyed by optimism surrounding a potential U.S.-Iran peace agreement, with major U.S. stock indexes like the Nasdaq Composite and Russell 2000 reaching record highs, driven in part by enthusiasm for AI-linked stocks. In this environment of rising investor sentiment and technological momentum, identifying high-growth tech stocks involves looking for companies that are well-positioned to capitalize on advancements in artificial intelligence and other innovative...
Abivax (ABVX) Jumps 16% on Bargain-Hunting
Abivax SA (NASDAQ:ABVX) is one of the 9 Stocks Crushing the Market With Surging Returns. Abivax soared by 16.39 percent on Thursday to close at $104.93 apiece as investors continued to hunt for bargains following the previous days’ lows, dragged by concerns about its cancer therapy candidate. Earlier in the week, Abivax SA (NASDAQ:ABVX) announced […]
European shares rise as oil slips, investors watch Middle East
By Johann M Cherian, Utkarsh Hathi and Ragini Mathur June 4 (Reuters) - European shares rose on Thursday as oil prices eased, although investors remained cautious on whether the latest developments in
Abivax (ABVX) Skyrockets 24% After Steep Fall
Abivax SA (NASDAQ:ABVX) is one of the 10 Stocks With Remarkable Resilience. Abivax soared by 24.34 percent on Wednesday to close at $90.15 apiece, as investors resorted to bargain-hunting to take advantage of its low price following its steep drop in the previous trading day, dragged by concerns about its cancer therapy candidate. Earlier in […]
This Stock Is Up 1,000% Over the Past Year. Is There More Upside Ahead?
A recent dip may turn out to be a great opportunity.